Commentary · 8 Jun 2026
Conference abstractPublished 18 Nov 2014
KEEPS cognitive and affective study: Effects of estrogen on cognition and mood in recently post menopausal Women
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
There is convincing evidence from animal and biomolecular studies that estrogen exerts multiple salutary actions on the brain, including neurotrophic, neuroprotective, anti-inflammatory, antioxidative and cognition-enhancing effects. However, results of clinical trials involving hormone therapy (HT) with or without progestins have been controversial. Findings from the seminal Women�s Health Initiative Memory Study (WHIMS) and others indicated that extended therapy with conjugated equine estrogen (CEE) and medroxyprogesterone (MPA) increased risk for heart disease, cognitive impairment and dementia in older postmenopausal women. To date, no single large study has evaluated the potential effects of HT in recently postmenopausal women in their mid-life. The NIH-funded KEEPS (Kronos Early Estrogen Prevention Study) Cognitive and Affective Study is the first study that compared the efficacy of two forms of estrogen and characterized the potential effects of 4 years of therapy with 0.45 mg/day of oral CEE (o-CEE), 50 mcg/day of transdermal estradiol (t-E2) and micronized progesterone (100 mg twice daily, given cyclically) on cognitive and mood function of 693 recently postmenopausal women (mean age: 52.7), within 3 years of their last menstrual period. The findings of the study indicated that administration of o-CEE was associated with significant improvements in mood-related symptoms, as measured by Profile of Mood Scales (POMS), including depression, anxiety and tension. Cognition as measured by an extensive battery of neuropsychological tests targeting domains reportedly sensitive to estrogen effects, showed no significant improvements; however, unlike WHIMS and other studies of HT, no adverse effects were found on any aspect of cognition. Administration of tE2 showed no effects, either on tests of mood or cognition. Overall, the results of the KEEPS Cognitive/Affective study indicated that therapy with o-CEE for up to 4 years, exhibits beneficial effects on measures of mood with no adverse effects on cognition. These results favorably alter the risk-benefit ratio of HT, and suggest that some of the most disabling symptoms of menopause can be effectively managed by o-CEE therapy in recently postmenopausal women overa limited period.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Alzheimers Disease & Parkinsonism.
Perspective · 8 Jun 2026
Oxidative Stress and Its Role in Neuronal Degeneration: Mechanisms and Implications
Commentary · 8 Jun 2026
Understanding the Pathophysiology of Prion-Induced Dementia
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Alzheimers Disease & Parkinsonism
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Sanjay Asthana”
- BylineArticles whose byline prints “Carey Gleason”
- BylineArticles whose byline prints “Maritza Dowling”
- BylineArticles whose byline prints “Whitney Wharton”